ObsEva Stock Price

0.02 (0.75%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ObsEva SA OBSV NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.13 -4.66% 2.66 2.65 2.85 2.85 2.79 19:42:01
Bid Price Ask Price Spread Spread % News
2.65 2.68 0.03 1.12% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,083 1,424,720 $ 2.72 $ 3,869,468 789,862 1.50 - 11.08
Last Trade Time Type Quantity Stock Price Currency
19:47:01 1 $ 2.68 USD

ObsEva Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 118.61M 44.59M 34.18M $ - $ - -2.50 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

ObsEva News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OBSV Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.187.012.653.105,141,288-1.52-36.36%
1 Month5.137.012.653.901,563,308-2.47-48.15%
3 Months2.,090,4870.5526.07%
6 Months3.687.011.503.60837,787-1.02-27.72%
1 Year10.8511.081.503.66622,397-8.19-75.48%
3 Years7.82320.351.505.26255,375-5.16-66.0%
5 Years13.2920.351.505.46231,102-10.63-79.98%

ObsEva Description

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The company is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. The is developing OBE2109 as a novel, oral gonadotropin-releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.